Aurinia Pharmaceuticals Inc. (AUPH) stock: key figures, P/E, revenue and dividend
Health Care · Canada · ISIN CA05156V1022
Aurinia Pharmaceuticals Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 283.06 m USD |
| Gross profit | 250.39 m USD |
| Operating income | 104.91 m USD |
| EBIT | 104.91 m USD |
| Net income | 287.20 m USD |
| Diluted EPS – continuing operations | 2.07 USD |
Full history since 1998, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
More stocks
- MFE-MEDIAFOREUROPE NV (MFEB.MI)
- UFP TECHNOLOGIES INC (UFPT)
- Chongqing Zongshen Power Machinery Co Ltd (001696.SZ)
- China Railway Special Cargo Logistics Co. Ltd. (001213.SZ)
- PERPETUA RESOURCES CORP. (PPTA)
- Shenzhen Everbest Machinery Indus (002980.SZ)
- BIEM.L .FDLKK Garment Co Ltd (002832.SZ)
- Pinnacle Investment Management Group Ltd (PNI.AX)
- Elite Semiconductor Memory Technology Inc (3006.TW)
- Cementir Holding NV (CEM.MI)
- Carmila SA (CARM.PA)
- Watches of Switzerland Group PLC (WOSG.L)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.